Women Are Leading the Future of Drug Development And That Changes More Than Representation

For a long time, conversations about women in drug development centered around one question: “How do we get more women into leadership?” While this is undoubtedly an important issue, I believe we are finally at a point where we should be shifting our focus to a different question.

What kind of future are women building now that they’re leading it?

After nearly two decades in oncology drug development, I’ve watched this shift happen in real time. When I first entered clinical research, many of the conference rooms I walked into were still predominantly male at the leadership level. While there were exceptional women, of course, they were often the exception rather than the norm. You noticed them because there were so few.

Today, the picture looks different. Some of the strongest medical monitors I’ve worked with are women. Many outstanding clinical scientists, project leaders, regulatory strategists, clinical operations professionals, medical writers, pharmacovigilance experts, and executives shaping oncology development are women. Moreover, an increasing number of people making some of the most important decisions in drug development are women.

This shift holds immense significance. It’s not because women inherently make better decision compared to men. Rather, it’s because diversity of experience profoundly influences the decision-making process. In drug development, better decisions save time, save resources, and ultimately improve patient care.

One thing I’ve learned throughout my career is that successful drug development isn’t driven by the loudest person in the room. Instead, it’s driven by the person asking the question nobody else thought to ask. 

I’ve watched women consistently bring a style of leadership that values curiosity over certainty, collaboration over hierarchy, and thoughtful discussion over unnecessary ego. That doesn’t mean decisions are softer. If anything, they’re often stronger. The best leaders I’ve worked with aren’t interested in proving they’re the smartest person at the table. Instead, they’re interested in making sure the team reaches the smartest decision.

Drug development is far too complex for any one person to have every answer. Medical monitors depend on statisticians, clinical operations depends on medical affairs, regulatory teams rely on safety physicians, and investigators depend on sponsors. Every successful trial is built on expertise that overlaps rather than competes. Leaders who recognize this tend to build more effective teams.

I’ve seen many women excel because they’re exceptionally good at creating environments where people feel comfortable challenging assumptions. Ironically, that’s exactly what science requires.

One misconception I still hear is that leadership means having all the answers. In reality, leadership is often about creating space for the right conversations to happen before mistakes occur. Some of the most valuable meetings I’ve ever participated in weren’t memorable because someone delivered a brilliant presentation. They were memorable because someone asked a simple question that completely changed the discussion. 

Questions like, “Are we interpreting this toxicity correctly?” “What happens if enrollment accelerates faster than expected?” “Have we considered how investigators will actually operationalize this protocol?” may not seem dramatic. However, they are practical questions that can prevent costly issues. I’ve found that many women leaders are remarkably comfortable asking those questions, even when they seem basic. That curiosity is a strength rather than a weakness.

As a medical monitor, I’ve also learned that influence rarely comes from authority alone. It comes from trust. Investigators don’t call you because your title says Medical Director. They call because they trust your judgment. Clinical operations doesn’t ask for your input because your name appears higher on the organizational chart. They ask because they know you’ll help solve the problem. Sponsors don’t remember every recommendation you make. Instead, they remember how you handled difficult decisions when the data were incomplete. Trust is built through one conversation at a time, one difficult eligibility decision, one safety review, one disagreement handled professionally, and one moment where you choose collaboration instead of defensiveness.

I’ve watched many women become exceptional leaders because they understand this concept. Influence isn’t something you announce, but rather it’s something other people give you after you’ve earned it.

One change I’m particularly excited about is seeing more women leading early-stage oncology development. Phase 1 studies demand a different type of leadership style. There are no established treatment algorithms, no mature survival curves, or decades of clinical experience to rely on. Every dose-escalation meeting involves uncertainty, every safety signal requires careful interpretation, and every recommendation carries meaningful consequences.

This environment values intellectual humility, it rewards curiosity, and it rewards people willing to change their minds when new evidence emerges. These are qualities I’ve consistently seen among many of the women leading today’s early development programs. Not because they’re women, but because they’re outstanding scientists who happen to lead that way.

I’ve also noticed another shift that’s harder to measure: the culture is changing. Years ago, leadership often felt transactional. Today, the strongest leaders I know spend just as much time thinking about people as they do about timelines. They care about developing junior colleagues, they create opportunities instead of guarding them, they mentor, they sponsor, and they introduce talented people into rooms where important decisions are being made. That’s one of the greatest gifts a leader can offer. 

No promotion I’ve received happened in isolation. At different points in my career, someone advocated for me when I wasn’t in the room. Someone believed I was ready before I believed it myself. Someone gave me an opportunity that exceeded my qualifications. These moments have left an indelible mark on me. 

As I’ve transitioned into leadership myself, I’ve realized that’s an integral part of the responsibility. Leadership isn’t just about delivering results. It’s about leaving the profession stronger than you found it. 

I believe we also need to redefine what leadership success looks like. For far too long, visibility was mistaken for impact. The person speaking the most wasn’t necessarily contributing the most, and the person with the strongest opinion wasn’t always making the best decision. Drug development has a way of exposing these flaws. Data eventually wins, and patients eventually remind us of what truly matters.

The most effective leaders I’ve worked with don’t need every decision to be their decision. They’re comfortable being wrong, they’re willing to listen, and they’re secure enough to change course when the evidence changes. That’s scientific leadership, and it’s something our industry needs more of.

People sometimes ask me what gives me the most hope about the future of oncology. While advancements like artificial intelligence, cell therapy, gene editing, bispecific antibodies, and radiopharmaceuticals certainly deserve attention, I believe one of the most significant reasons for my optimism lies in the people driving these innovations.

I see more women sitting at tables where major development decisions are made, more women leading global programs, and more physician-scientists, operational leaders, statisticians, safety experts, and executives bringing different perspectives to increasingly complex problems. This shift is good for science, for patients, and for our industry.

Breakthroughs in drug development don’t happen simply because we invent better drugs. They happen because thoughtful people ask better questions, challenge assumptions, collaborate across disciplines, and make difficult decisions with patients at the center rather than personal egos. 

This is the future of drug development I want to be part of, and from where I sit, that future is already taking shape.